Paroxysmal Nocturnal Hemoglobinuria (PNH)
Caroline Piatek, MD
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study
The Phase 3 single-arm COMMODORE 3 study (ClinicalTrials.gov, NCT04654468) evaluated efficacy and safety of crovalimab crovalimab: An ex
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa
2023 Salt Lake City Patient and Family Conference
Thank you for attending the 2023 Salt Lake City Patient and Family Conference. We will keep uploading presentations as we receive them, please keep checking back for updates.
Presentation Materials:
Predisposition to Inherited Bone Marrow Failure Syndromes
Aplastic Anemia and Non-Transplant Therapies
Patient Panel: Addressing Patient Challenges and Barriers - Patient & Family Conference Utah 2023
Ask the Pediatric Experts: Session from the Patient and Family Conference in Salt Lake City, UT 2023
PNH and Non-Transplant Therapies from the Patient and Family Conference in Salt Lake City, UT 2023
Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023
Evaluation of the Quality of Life and Treatment Experiences of Patients with Paroxysmal Nocturnal Hemoglobinuria
The purpose of the study is to learn what it is like to have PNH and being treated with for PNH. Individuals who participate in the study will complete an online survey about what it is like to live with PNH. The survey will take about 45 minutes. Participants may also be asked to take part in a one-hour interview by telephone or computer. The interviewer will ask questions about what it is like to have, and be treated for, PNH. No medical treatment of any kind will be given as part of this study.
Hello!
